EGFR COX 2 expression and MVD with early stage non-small cell lung cancer prognosis.docVIP

 PAGE \* MERGEFORMAT 17 EGFR COX 2 expression and MVD with early stage non-small cell lung cancer prognosis Authors: PENG Jie Wen, Zhang Kai, SUN Shi-Jun, LIANG Han-Lin, Xiao Jian-jun 【Key Words】 MVD Keywords:: Lung neoplasms; Epidermal growth factor receptor; Cyclooxygenase  2; Microvessel density Abstract: Objective To study the EGFR (epidermal growth factor receptor), COX  2 (COX- 2), and MVD (microvessel density) with early stage non-small cell lung cancer (NSCLC) in disease-free survival relationship. Methods Retrospective analysis of 36 cases of NSCLC patients after pathological specimens, using immunohistochemistry to detect the EGFR, COX  2 and MVD (with CD34-specific marker) expression. The results of EGFR and COX  2 positive expression rates were 44% and 53% respectively. This indicator are related to disease-free survival was no significant relationship. MVD mean 65.3, standard deviation of 17.6, to the average community is divided into high expression and low expression group. MVD high expression of it has led to a shorter disease-free survival trend (P = 0.08). EGFR-/ COX  2 + / MVD high expression of early NSCLC disease-free survival significantly lower (P = 0.04). Conclusion COX  2 and high MVD expression and low expression of EGFR may be at high risk early stage NSCLC will require more aggressive adjuvant chemotherapy. Keywords:: lung cancer; epidermal growth factor receptor; oxide synthase  2; microvessel density At present the NSCLC clinical stage T1N0M0 the need for postoperative adjuvant chemotherapy there is a big controversy, most people think of them high-risk patients need chemotherapy. With the progress of molecular biology, more accurate prognostic indicator is gradually uncovered. EGFR (epidermal growth factor receptor) is the research hot spot, its occurrence in the process of tumor blood vessels play an important role, Tateishi so that the EGFR autocrine pathway reduces the